N/A N=198 Chest Tube Drainage of Transudative Pleural Effusions Hastens Liberation From Mechanical Ventilation
Liberation From Mechanical Ventilation
Primary: Total Days of Mechanical Ventilatory Support — 6.51; 4.02 days
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=27 Intrapleural Fibrinolytic Therapy to Enhance Chemical Pleurodesis Enhance Chemical Pleurodesis
Pleural Effusion
Primary: Chest X-ray Results on Day 3 After Pleurodesis — 5; 6; 5; 8 Participants — p=0.863
N/A N=100 Efficacy and Safety of Activase (Ateplase) vs Placebo in Complicated Pleural Effusions (CPE)/Empyemas
Pleural Effusion Associated With Pulmonary Infection · Bacterial Pleural Effusion Other Than Tuberculosis
Primary: No Surgical Intervention — 66; 6 participants — p=<0.001
Phase 3 N=72 Intrapleural Bevacizumab and Cisplatin Therapy for Malignant Pleural Effusion Caused by Non-small Cell Lung Cancer
Malignant Pleural Effusion
Primary: Number of Participants With "Complete Response" and "Partial Response" — 17; 2; 13; 15 participants
Phase 4 N=32 Fibrinolysis Compared to Thoracoscopy for Pleural Infection
Pleural Infection · Empyema · Pleural Diseases
Primary: Duration of Hospital Stay After Intervention — 4; 2 days
N/A N=50 Sensitivity of PDL-1-analysis From Pleural Effusion in Non-small Cell Lung Cancer
Lung Neoplasms
Primary: PD-L1 Prevalence IHC — 21; 14; 8; 27 Participants
N/A N=37 Pleural Manometry for the Characterization of Spontaneous and Tension Pneumothorax
Pneumothorax · Tension Pneumothorax
Primary: Pleural Pressure (Ppl) Prior to Evacuation of Pleural Air — 7.44; -1.79 cmH2O
Phase 4 N=5 Fibrinolytic Therapy Versus Medical Thoracoscopy
Pleural Diseases
Primary: Number of Hospital Days for Required to Treat Complicated Parapneumonic Effusions or Pleural Empyema. — 13; 18.5 days
N/A N=119 Safety and Effectiveness of a New Pleural Catheter for Symptomatic, Recurrent, MPEs Versus Approved Pleural Catheter
Malignant Pleural Effusion
Primary: The Proportion of Subjects Achieving Pleurodesis Without Recurrence. — 17; 12 Participants
N/A N=21 Lung Ultrasound in PD Patients
Peritoneal Dialysis · Hypervolemia · VEGF Overexpression
Primary: Association Between Number of Kerley B Lines by Ultrasound and Serum VEGF-C Level (pg/ml) by Enzyme-linked Immunosorbent Assay — 0.29; 0.25; 0.33 ng/ml — p=0.039
Phase 2 N=31 Study of Pemetrexed in Mesothelioma and Lung Cancer Patients With Fluid Around the Lungs or Abdomen
Non-small Cell Lung Cancer · Mesothelioma · Lung Neoplasms
Primary: Overview of Adverse Events — 28; 23; 12; 1 participants
N/A N=25 Catheter Placement for Hepatic Hydrothorax
Pleural Effusion
Primary: Feasibility of Using Indwelling Tunneled Pleural Catheters for the Management of Hepatic Hydrothorax — 25 Participants
Phase 2 N=33 Hemodynamics and Extravascular Lung Water in Acute Lung Injury
Acute Lung Injury
Primary: The Primary Efficacy Variable Will be the Total Reduction in Measured Lung Water
N/A N=10 Treatment of Complicated Parapneumonic Effusion With Fibrinolytic Therapy Versus VATs Decortication
Parapneumonic Effusion · Empyema, Pleural · Coagulopathy
Primary: Hospital Length of Stay — 12.4; 8.4 days
N/A N=186 Thoracic Ultrasonography for Pulmonary Edema in Patients With Pre-Eclampsia
Pre-eclampsia
Primary: Detection of Fluid in the Lungs — 2; 3 Participants — p=.162
Phase 4 N=121 PleuraSeal Post Market Study (Europe)
Lung Disease · Pulmonary Lobectomy
Primary: Percentage of Subjects Remaining Air Leak Free From Time of Skin Closure to Hospital Discharge. — 41.9; 30.5 Percentage of participants — p=0.257
Phase 2 N=130 B-lines Lung Ultrasound Guided ED Management of Acute Heart Failure Pilot Trial
Heart Failure · Heart Failure Acute · Acute Cardiac Pulmonary Edema
Primary: Number of Participants With B-lines ≤ 15 at the Conclusion of ED AHF Management — 7; 10 Participants
Phase 3 N=97 Intrapleural DNase and Tissue Plasminogen Activator in Pediatric Empyema (DTPA Trial)
Pleural Empyema
Primary: Time to Hospital Discharge — 9.0; 9.1 days
N/A N=59 Mini Invasive Endomicroscopy of the Pleura for Malignancies Diagnosis
Pleural Diseases · Pleural Neoplasms
Primary: Malignant Pleural Infiltration Identification — 12; 27; 9; 4 Participants — p=0.023
N/A N=490 Active Clearance of Chest Tubes After Cardiac Surgery: A Prospective Randomized Controlled Study
Atrial Fibrillation · Pericardial Effusion · Pleural Effusion
Primary: Number of Participants With Postoperative Atrial Fibrillation — 39; 33 Participants
N/A N=47 FAST (Fluid Accumulation Status Trial)
Congestive Heart Failure · Cardiomyopathy · Dyspnea
Primary: Number of Subjects With at Least 30 Days of Daily Impedance Measurements — 47; 106 participants
N/A N=106 FlowTriever Pulmonary Embolectomy Clinical Study
Pulmonary Embolism · Acute Pulmonary Embolism · Submassive Pulmonary Embolism
Primary: Change in RV/LV Ratio — 0.38 RV/LV ratio — p=< 0.0001
N/A N=109 Prospective Evaluation of 14F Thal Tube vs 28 French Chest Tube for Hemothorax and Use of Maximum Barrier Precautions
Hemothorax · Hemopneumothorax; Traumatic · Empyema
Primary: Number of Participants With Retained Hemothorax Following Initial Chest Tube Placement Requiring Intervention — 51; 48 Number of Participants — p=0.036
N/A N=65 Probe Based Confocal Laser Endomicroscopy During Thoracoscopy for Pleural Malignancies Diagnosis.
Pleural Carcinomatosis
Primary: Pleural Carcinomatosis Identification (Compared to Standard Biopsies). Qualitative Criteria. — 8; 24; 21; 0 Participants — p=0.0003
Phase 2 N=59 Effects of Carboplatin and Gemcitabine on Stage IIIB Pleural Effusion and Stage IV Lung Cancer
Stage IV Non-small Cell Lung Cancer · Stage IIIB Non-small Cell Lung Cancer
Primary: Percentage of Participants With Reduction in Grade 3/4 Neutropenia — 40; 13 percentage of participants
Phase 4 N=40 Evaluating Fluid Strategies in Thoracic Surgery Patients Utilizing a Goal Directed Approach
Hypotension · Kidney Injury
Primary: Development of Renal Injury — 0.8; 0.74 mg/dL — p=0.31
N/A N=100 Vacuum vs Manual Drainage During Unilateral Thoracentesis
Pleural Effusion · Pleural Diseases · Thoracic Diseases
Primary: Pain Change — 0.53; 1.43 Pre-post NPRS Pain Scale Score
Phase 3 N=44 The Effects of Inhaled Nitric Oxide After Fontan Operation
Congenital Heart Defect
Primary: Length of Hospital Stay Following Fontan — 11.2; 11 days
N/A N=25 EPIONE Guided Lung Evaluation
Lung Cancer
Primary: Feasibility of the Device — 26 Number of targets reached
N/A N=260 Comparison Of Chest Ultrasound Techniques To Identify Clinically Significant Pneumothorax
Pneumothorax
Primary: Pneumothorax (Positive or Negative) — 17; 21 participants